Efficacy outcomes between tarlatamab and real-world physicians' choice of therapies for previously treated extensive stage small cell lung cancer.

ABSTRACT:

Background

Tarlatamab, a bispecific T-cell engager immunotherapy, showed durable response with promising survival outcomes in patients with previously treated small cell lung cancer (SCLC) in the phase 2 DeLLphi-301 study. Given the lack of a comparator in DeLLphi-301, this analysis aimed to evaluate the relative efficacy of tarlatamab against physicians' choice of therapies in real-world practice.

Patients and methods

This analysis compared the outcomes of patients in DeLLphi-301 who received tarlatamab 10 mg (n = 97) with patients in real-world cancer clinics captured in the Flatiron Health database who received third or later-line comparator therapies for SCLC (n = 184). Propensity score weighting was used to adjust for differences in key prognostic factors between cohort

SUBMITTER: Wang J 

PROVIDER: S-EPMC12459094 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature